Michael Deininger, MD
Enriched profileExecutive Vice President and Chief Scientific Officer, Versiti Blood Research Institute; Professor, Division of Hematology, Department of Medicine, Medical College of Wisconsin · Versiti Blood Research Institute
Michael Deininger is Executive Vice President and Chief Scientific Officer, Versiti Blood Research Institute; Professor, Division of Hematology, Department of Medicine, Medical College of Wisconsin at Versiti Blood Research Institute. OpenAlex indexes 883 publications with 53,068 citations (h-index 101); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 12 Oct 2026
Overview
Updated 14 Oct 2026
Michael Deininger, MD, is Executive Vice President and Chief Scientific Officer, Versiti Blood Research Institute. The public record shows 883 publications with 53,068 citations (h-index 101), centered on Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2026–2026).
- Most recent indexed publication: 2026 · Leukemia
- Top research focus: Chronic Myeloid Leukemia Treatments
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 35 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 332.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Vice Chair
National Comprehensive Cancer Network (NCCN) CML Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.utah.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Sponsor: University of Utah
- Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Sponsor: OHSU Knight Cancer Institute
Industry payments
Updated 14 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20252 payments$24,323openpaymentsdata.cms.gov ↗
- SANOFI US SERVICES INC.Program year20251 payment
- PFIZER INC.Program year20251 payment
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Sprycel60%Bosulif40%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- The function of MS4A3 in normal and malignant hematopoiesis
University of Michigan at Ann Arbor
FY2026$505,191R01CA268496 - The function of MS4A3 in normal and malignant hematopoiesis
Versiti Blood Health, Inc.
FY2025$473,053R01CA268496 - Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL
Versiti Blood Health, Inc.
FY2025$377,438R01CA257602
Congress activity
Updated 14 Oct 2026
116 congress contributions (2007–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Enhanced tyrosine kinase inhibitor response on chronic myeloid leukemia cells upon MS4A3 mRNA delivery
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors.
Blood cancer journal
Letter2026
Most-cited works
by citation count (OpenAlex)- 01Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaArticle3,488 citations2006
- 02A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisArticle2,095 citations2012
- 03European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Article1,986 citations2013
- 04The molecular biology of chronic myeloid leukemiaArticle1,666 citations2000
- 05European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaArticle1,535 citations2020
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
versiti.org/about-us/versiti-leadership-team/michael-deininger
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →versiti.org ↗ - Other
mcw.edu/find-a-doctor/deininger-michael
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mcw.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- PhD
Imperial College London (1995), Thesis: Signal transduction and imatinib as molecularly targeted therapy for chronic myeloid leukemia
1995verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.utah.edu ↗
- Member
American Society of Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗ - Member
European Hematology Association
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗ - Member
European Leukemia Net
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗
- ASH Scholar
American Society of Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗
Secondary affiliations
appointments beyond the home institution- Adjunct Professor
Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗ - Associate Dean of Research
Medical College of Wisconsin
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗ - Mike and Cathy White Endowed Chair
Versiti Blood Research Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center